BLS Pharmaceuticals Expands Psychedelic Medicines Platform Through Cayman Chemical Referral Agreement

International Referral Agreement Strengthens BLS's Psychedelic Manufacturing Position

BLS Pharmaceuticals has announced that its wholly owned subsidiary, BLS Wholesalers Pty Ltd, has entered into a Referral Agreement with Cayman Chemical Company Incorporated, a globally recognised supplier of pharmaceutical-grade research chemicals and active pharmaceutical ingredients. The agreement establishes a commercial referral framework under which Cayman will introduce prospective customers seeking finished pharmaceutical dosage forms of psilocybin and MDMA to BLS, while BLS will manufacture and supply patient-ready dosage products in accordance with applicable regulatory requirements. This referral arrangement creates an additional international customer acquisition channel for BLS's pharmaceutical manufacturing business.

Cayman Chemical, founded in 1980 and headquartered in Ann Arbor, Michigan, serves pharmaceutical companies, biotechnology developers, academic institutions and government laboratories worldwide, supporting drug discovery, clinical research and pharmaceutical manufacturing across a broad range of therapeutic areas. The new Referral Agreement complements the Company's existing API Supply Agreement with Cayman and expands BLS's international commercial platform at a critical time for the psychedelic therapeutics sector. Managing Director Sam Watson noted that the relationship highlights the quality of BLS's GMP manufacturing platform, regulatory expertise and global pharmaceutical fulfilment capabilities that the company has established.

Cayman Partnership Reflects Growing Industry Recognition of BLS's Manufacturing Capabilities

The announcement suggests that Cayman Chemical's decision to refer customers to BLS reflects recognition of the company's manufacturing credentials and regulatory approvals in the psychedelic therapeutics space. BLS currently holds manufacturing licences and regulatory approvals required for this emerging sector and operates as a significant supplier of pharmaceutical-grade MDMA and psilocybin products used within Australia's regulated psychedelic medicines framework under the Therapeutic Goods Administration's Authorised Prescriber Scheme. This established regulatory position provides BLS with a competitive advantage as international markets begin to develop their own frameworks for psychedelic therapeutics.

BLS operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products. The company maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners. The Cayman referral arrangement positions BLS to leverage this existing international infrastructure to meet customer demand from the US and other markets for finished psychedelic medications, creating a new revenue stream through customer introductions facilitated by a respected global pharmaceutical ingredient supplier.

Eli Lilly's US$3.8 Billion AtaiBeckley Acquisition Signals Industry Momentum

The Referral Agreement with Cayman Chemical comes at a time of rapidly increasing global investment in psychedelic therapeutics. Last week, Eli Lilly and Company announced a definitive agreement to acquire AtaiBeckley Inc. for consideration of up to US$3.8 billion, representing the largest pharmaceutical transaction completed in the psychedelic therapeutics sector to date. This major acquisition by one of the world's largest pharmaceutical companies demonstrates significant commercial and strategic confidence in the therapeutic potential of psychedelic medicines for addressing mental health conditions.

The AtaiBeckley transaction follows AbbVie's US$1.2 billion acquisition of Gilgamesh Pharmaceuticals in 2025, reflecting increasing investment by major pharmaceutical companies in next-generation mental health therapies. These developments highlight the growing commercial and strategic importance of psychedelic therapeutics within the global pharmaceutical industry. For BLS, the acceleration of industry investment provides validation of the market opportunity and potential demand for quality pharmaceutical-grade manufacturing and supply capabilities. Managing Director Sam Watson indicated that transactions like Eli Lilly's acquisition confirm the direction the industry is heading, suggesting this is an appropriate time for BLS to evaluate expansion opportunities across the psychedelic therapeutics sector.

Australia's Regulated Pathway Establishes BLS as Early Market Leader

Australia remains one of the first countries globally to establish a regulated pathway permitting authorised psychiatrists to prescribe MDMA and psilocybin for eligible patients under the Therapeutic Goods Administration's Authorised Prescriber Scheme. This early regulatory framework has enabled BLS to develop manufacturing capabilities, obtain necessary licences, and establish itself as a significant supplier within Australia's regulated psychedelic medicines market. The company's existing experience operating within this regulatory environment provides valuable expertise as international markets begin to develop comparable frameworks for psychedelic therapeutics.

BLS's established position within Australia's regulated market has provided the company with operational experience, regulatory credentials, and manufacturing capabilities that now position it to serve international customers as global demand for pharmaceutical-grade psychedelic medicines increases. The Cayman Chemical referral arrangement capitalises on this existing regulatory positioning by connecting BLS with international customers seeking finished dosage forms. Managing Director Sam Watson stated that the company has held the manufacturing licences and regulatory approvals this sector needs for some time, emphasising that BLS is already supplying patient-ready products within Australia's regulatory framework and is therefore well-positioned to service international markets as they develop comparable regulatory pathways.

Planned Expansion into 5-MeO-DMT Development and Strategic Partnerships

Building on its GMP manufacturing platform, regulatory licences and expanding international commercial relationships, BLS intends to evaluate opportunities to strengthen its position across the psychedelic therapeutics sector. The company has identified several strategic areas for potential development, including 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and psilocybin product development, strategic partnerships with biotechnology companies and academic research institutions, and contract development and manufacturing opportunities. These evaluation activities suggest BLS's management believes there is potential to expand beyond its current focus on MDMA and psilocybin to include other psychedelic compounds with therapeutic potential.

The company also plans to undertake intellectual property and freedom-to-operate assessments as part of its evaluation of broader opportunities across the psychedelic therapeutics sector. This suggests BLS may be considering development of proprietary formulations, delivery mechanisms, or intellectual property positions that could differentiate its offerings in what is expected to become an increasingly competitive market. The announcement indicates that BLS will continue supporting existing customers while assessing these opportunities, signalling that the company is not abandoning current commercial activities while evaluating new growth avenues. The specific mention of 5-MeO-DMT product development and partnerships with biotechnology companies and academic institutions suggests BLS is considering positioning itself as a comprehensive manufacturing and development partner for psychedelic therapeutics companies globally.

BLS's Global Manufacturing and Distribution Platform Spanning Multiple Markets

Breathe Life Sciences, the wholly owned subsidiary through which BLS operates its manufacturing business, was established in 2018 and has developed an international pharmaceutical manufacturing and distribution platform with operations across Australia, Japan, Scotland (United Kingdom) and Europe. The subsidiary is a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA, and specialises in final dose-form manufacturing, pharmaceutical distribution, contract manufacturing, international supply and the development of regulated therapeutic products. This geographically distributed operational footprint provides BLS with manufacturing and distribution capabilities across multiple regulated markets, enabling the company to serve customers across different jurisdictions.

BLS sources pharmaceutical raw materials and active pharmaceutical ingredients from a global supplier network and manufactures products for both its own brands and third-party customers. This business model positions the company to serve customers seeking contract manufacturing services for psychedelic medicines as well as customers seeking supply of finished pharmaceutical products. The company's existing international operations in Europe, the United Kingdom and Japan suggest that BLS may already have established relationships with pharmaceutical regulators and distribution networks in these jurisdictions, which could facilitate expansion of psychedelic medicines supply as regulatory pathways emerge in these markets.

Referral Framework Establishes New Customer Acquisition Channel for Manufacturing Services

The Referral Agreement with Cayman Chemical creates an additional international customer acquisition channel for BLS's pharmaceutical manufacturing business and complements the company's existing commercial supply activities. Under the framework, Cayman will introduce prospective customers seeking finished pharmaceutical dosage forms of psilocybin and MDMA to BLS for manufacturing and supply. This referral model leverages Cayman's existing relationships with pharmaceutical companies and biotechnology developers globally while providing these customers with a trusted source for pharmaceutical-grade finished psychedelic medicines manufactured according to applicable regulatory requirements.

The agreement's focus on customer referrals from the US and other international markets suggests significant potential demand for quality pharmaceutical-grade finished dosage forms of MDMA and psilocybin outside Australia. As the US and other jurisdictions develop their own regulatory frameworks for psychedelic medicines, the demand for contract manufacturing and supply of finished pharmaceutical products is expected to increase. By establishing this referral relationship with Cayman Chemical, a globally recognised supplier with existing relationships throughout the pharmaceutical industry, BLS positions itself to capture a portion of this anticipated international demand without requiring BLS to develop its own direct sales and marketing capabilities in these markets.

Integration of Referral Agreement with Existing API Supply Relationship

The announcement indicates that the new Referral Agreement complements an existing API Supply Agreement between BLS and Cayman Chemical. This suggests that BLS and Cayman already have an established commercial relationship involving the supply of active pharmaceutical ingredients. The addition of the referral framework builds on this existing relationship, expanding from ingredient supply to include finished dosage form referrals. This progression suggests a deepening commercial partnership between the two companies and indicates that Cayman has sufficient confidence in BLS's manufacturing capabilities and regulatory compliance to introduce customers seeking finished pharmaceutical products.

The structure of complementary agreements—an existing API Supply Agreement combined with the new Referral Agreement—suggests a multi-layered commercial relationship that may benefit both parties. Cayman Chemical maintains its role as a supplier of pharmaceutical-grade ingredients while also serving as a commercial referral partner introducing customers to BLS for finished product manufacturing and supply. For BLS, the arrangement provides both the raw materials needed for manufacturing through the API Supply Agreement and a channel for acquiring new customers for its finished product manufacturing services through the Referral Agreement. This integrated approach to the commercial relationship demonstrates alignment between the two parties' commercial interests in the emerging psychedelic therapeutics market.